Placebo-controlled oral pulse prednisolone therapy in alopecia areata

Kar, Bikash Ranjan; Handa, Sanjeev; Dogra, Sunil; Kumar, Bhushan

doi:10.1016/j.jaad.2004.10.873

Cited by 125 publications

(100 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The first controlled study with 43 patients, who received 200 mg oral prednisolone pulse therapy weekly against placebo over 6 months, detected a significant hair regrowth obtained in 8 patients in the prednisolone-treated group and none in the placebo group. 19 Two of the responders experienced a relapse during the observation period of 3 months. However, an intention-to-treat re-analysis found the response not to be significant.…”

Section: Resultsmentioning

confidence: 97%

“…11,12 Systemic oral corticosteroids have been reported to be effective in extensive AA, but relapses occurred when the dosage was reduced. [13][14][15][16][17][18][19] In order to avoid the side effects of prolonged use of steroids, pulse corticosteroid therapy has been introduced in the treatment of AA by Burton and Shuster in 1975. 20 Various doses and schemas of steroid pulse therapy have been tried ever since.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Medium-dose prednisolone pulse therapy in alopecia areata

Efentaki¹,

Altenburg²,

Haerting³

et al. 2009

Dermato-Endocrinology

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

Medium-dose prednisolone pulse therapy in alopecia areata

Efentaki¹,

Altenburg²,

Haerting³

et al. 2009

Dermato-Endocrinology

View full text Add to dashboard Cite

“…[2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] Recently, the use of biologics and laser therapy in alopecia areata have shown some beneficial results. [21][22][23] There has been a recent spurt in application of platelet-rich plasma (PRP) in dermatology and aesthetic medicine.…”

Section: Introductionmentioning

confidence: 99%

A clinical study on alopecia areata

Ninama¹,

Mahajan²,

Bilimoria³

et al. 2018

Int J Res Dermatol

View full text Add to dashboard Cite

Background: Alopecia areata (AA) is a common auto-immune condition, causing hair loss. This disease has limited treatment modalities. Through this study, comparison between established modalities of treatment such as oral mini pulse therapy, intralesional corticosteroids and platelet-rich plasma (PRP) as a newer modality has been done. The objective of the study was to evaluate the efficacy and safety of various treatment modalities in alopecia areata.Methods: 45 patients with alopecia areata presenting to the OPD of Dermatology, Dhiraj hospital, Pipariya were included in this study. It was conducted as a randomized prospective study for a period of 16 weeks. After taking informed consent, patients were randomly distributed into three treatment groups. Group 1 patients were treated with Tab. Betamethasone 0.1 mg/kg every Saturday and Sunday, Group 2 was treated with Inj. Triamcinolone acetonide 10 mg/ml for scalp and 2.5 mg/ml for eye brows and face was injected into deep dermis; Group 3 was treated with Dermaroller followed by application of activated platelet rich plasma (PRP). SALT score was calculated at first visit and 16 weeks. Regrowth was calculated using Mac Donald and Null Horis grading Scale at 16 weeks.Results: The SALT score reduced from 13.27 to 7.52 in Group 1, 13.93 to 8.16 in Group 2 and 42.32 to 21.12 in Group 3. Mean grade of regrowth of hairs observed was 3.47, 3.80, 2.93 in Group 1, 2, 3 respectively. The results were analysed using paired t test.Conclusions:Intralesional corticosteroids viz. triamcinolone acetonide still remains the first choice of therapy for AA in adults with limited involvement. Systemic corticosteroids give lower response than intralesional steroids. Platelet Rich Plasma (PRP) showed promising results, especially in children and in extensive involvement. Compared to other treatment modalities Inj. PRP is safe and with less side effects.

show abstract

“…26,27 Systemically, betamethasone and prednisolone are commonly used as mini pulse therapies. 28,29 Other modalities found effective in the treatment of AA include topical minoxidil, 30,31 oral and topical psoralen and ultraviolet A (PUVA), turban PUVA, topical diphenylcyclopropenone as contact-sensitizing immunotherapy, 32 methotrexate, azathioprine, 16 platelet-rich plasma, 33 sulfasalazine, 34 narrow band ultraviolet B, and bexarotene gel. 35 Biologics are ineffective and may cause aggravation during therapy.…”

Section: Mgmjmsmentioning

confidence: 99%

Alopecia Areata: An Update

Jerajani¹,

Rohatgi²,

Agrawal³

2017

MGM Journal of Medical Sciences

View full text Add to dashboard Cite

Alopecia areata (AA) is a very common autoimmune disease that leads to unpredictable, relapsing patchy hair loss. Its chronic pathophysiology is still not fully understood. Hair follicles are not destroyed permanently due to which the potential for regrowth of hair is retained for many years, and is possibly lifelong. Clinical presentation varies from small alopecia patches most commonly on the scalp to full body involvement. Characteristic "swarm of bees" appearance on histopathology is confirmatory in acute cases. A variety of therapeutic options are available, but search for new modalities continues as there is a high relapse rate and a number of side effects associated with the available treatment options.

show abstract

Placebo-controlled oral pulse prednisolone therapy in alopecia areata

Cited by 125 publications

References 18 publications

Medium-dose prednisolone pulse therapy in alopecia areata

Medium-dose prednisolone pulse therapy in alopecia areata

A clinical study on alopecia areata

Alopecia Areata: An Update

Contact Info

Product

Resources

About